Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-25
2005-10-25
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263380, C544S276000, C544S280000
Reexamination Certificate
active
06958344
ABSTRACT:
The invention provides certain heterocyclic compounds, processes, and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).
REFERENCES:
patent: 3318900 (1967-05-01), Janssen
patent: 4126689 (1978-11-01), Sanczuk et al.
patent: 4278677 (1981-07-01), Nedelec et al.
patent: 4410528 (1983-10-01), Teranishi et al.
patent: 5521197 (1996-05-01), Audia
patent: 6172067 (2001-01-01), Ito et al.
patent: 6248755 (2001-06-01), Chapman et al.
patent: 6329381 (2001-12-01), Kurimoto et al.
patent: 6407121 (2002-06-01), Nagamine et al.
patent: 6432981 (2002-08-01), Finke et al.
patent: 2003/0032642 (2003-02-01), Bonnert et al.
patent: 2003/0119869 (2003-06-01), Burrows et al.
patent: 2004/0157853 (2004-08-01), Bonnert
patent: 2331 223 (1974-01-01), None
patent: 4119767 (1992-12-01), None
patent: 0 293 078 (1988-11-01), None
patent: 0 447 324 (1991-09-01), None
patent: 0 778 277 (1997-06-01), None
patent: 1 069 124 (2001-01-01), None
patent: 1 122 257 (2001-08-01), None
patent: 2359079 (2001-08-01), None
patent: 51-88994 (1976-08-01), None
patent: WO 97/40035 (1997-10-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/17773 (1999-04-01), None
patent: WO 99/36421 (1999-07-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/08013 (2000-02-01), None
patent: WO 00/09511 (2000-02-01), None
patent: WO 00/38680 (2000-07-01), None
patent: WO 00/39129 (2000-07-01), None
patent: WO 00/45800 (2000-08-01), None
patent: WO 00/59502 (2000-10-01), None
patent: WO 00/76514 (2000-12-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO 01/25200 (2001-04-01), None
patent: WO 01/25242 (2001-04-01), None
patent: WO 01/58907 (2001-08-01), None
patent: WO 01/62758 (2001-08-01), None
patent: WO 200158906 (2001-08-01), None
patent: WO 200166525 (2001-09-01), None
patent: WO 200283693 (2002-10-01), None
patent: 03024966 (2003-03-01), None
patent: WO 03024966 (2003-03-01), None
Chemical Abstracts, vol. 54, No. 10, May 1960, Abstract No. 9933f, C. Wayne Noell and Roland K. Robins, “Potential Purine Antagonists XVII. Synthesis of 2-methyl and 2-methylthio-6, 8-disubstituted purines”, see formula III when R-SMe, R1=C1, R2=OH.
U.S. Appl. No. 10/486,503, Bonnert et al. filed Feb. 11, 2004.
Ahmed et al., “Novel synthesis of 1-aryl-9-alkyl-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[2,3-b]quinoxalines by lithium aluminum hydride reduction of N-phenyl-1-benzimidazolylsuccinimides”, CAPLUS 79:92106 (1973).
Cohen et al., “Cytokine function: A study in biologic diversity”, CAPLUS 125:31527 (1996).
Cowley et al., “Preparation of 1-(3-phenyloxpropyl)piperdine derivatives as opioid receptor ligands”, CAPLUS 138:39189 (2002).
Finke et al., “Preparation of piperidinylmethylcyclopentanes as modulators of CCR-5 and/or CCR-3 chemokine receptors”, CAPLUS 134:56576 (2000) CAS Listing, 77 answers.
Fukuda et al., “Preparation of benzotriazole derivatives as cardiovascular agents and antipsychotics”, CAPLUS 123:340149 (1995).
Gewald et al., “New Synthesis of Substituted 4-Amino-quinazolines and Their Heteroanaloga”,J. prakt. Chem. 338:206-213 (1996).
Grant, “University of Minnesota—Twin Cities Campus College of Pharmacy, Annual Report”, [online] 1999, [retrieve on Feb. 13, 2003]. Retrieved from the internet, http://www.msi.umn.edu/general/Reports/ar99/departments/pharmacy.html.
Kiriasis et al., “Synthesis and Properties of New Pteridine Nucleosides”,Dev. Biochem. 4:49-53 (1978).
McNaught et al., “IUPAC Compendium of Chemical Terminology, 2ndEd” (1997), Entry for “leaving group”.
Ott et al., “4-amino-7, 8-dihydro-2-(methylmercapto)-8-β, -D-ribofuranosylpteridin-7-One, Modified Fusion Reaction with Trimethylsilylated Pteridine Derivatives”,Nucl. Acid. Chem. 2:735-739 (1978).
Ott et al., “Zur Synthese des 4-Amino-7-oxo-7, 8-dihydropteridin-N-8-β-D-ribofuranosids—ein strukturanaloges Nucleosid des Adenosins”,Chem.Ber. 107:339-361 (1974).
Patent Abstracts of Japan, abstract of JP-5-202047 A (Chugai Pharmaceut. Co. Ltd.) Aug. 10, 1993.
Sato et al., “Psychotropic agents. 3. 4-(4-Substituted piperidinyl)-1-(4-flurophenyl)-1-butanones with potent neuroleptic activity”, CAPLUS 89:208915 (1978).
Sato et al., “Psychotropic Agents, 3. 4-(4-Substituted piperidinyl)-1-(4-flurophenyl)-1-butanones with Potent Neuroleptic Activity,”Journal of Medicinal Chemistry21(11):1116-1120 (1978).
Taylor et al., “Molecular Determinants for Recognition of RU 24969 Analogs at Central 5-Hydroxytryptamine Recognition Sites: Use of a Bilinear Function and Substituent Volumes to Describe Steric Fit,”Molecular Pharmacology32:42-53 (1988).
Teranishi et al., “Piperidine derivatives and pharmaceutical compositions containing them”, CAPLUS 95:132947 (1981).
Trivedi et al.,Annual Reports in Medicinal Chemistry35:191-200 (2000).
Vandenberk et al., “1-(Benzazolylalkyl)piperidines and their salts with acids”, CAPLUS 87:23274 (1977).
Vartanyan et al., “Synthesis and biological activity of 1-substituted benzimidazole and benztriazole derivatives”, CAPLUS 98:4503 (1983).
West, “Solid State Chemistry and its applications”, pp. 358, 365 (1988).
Bonnert Roger
Cage Peter
Hunt Fraser
Walters Iain
Willis Paul
AstraZeneca AB
Berch Mark L.
Fish & Richardson P.C.
LandOfFree
Pyrimidine compounds and their use as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine compounds and their use as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine compounds and their use as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3453404